ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy

Basit Öğe Kaydı
dc.contributor.authorOzdemir, Ozer
dc.contributor.authorOzdemir, Pelin
dc.contributor.authorVeral, Ali
dc.contributor.authorUluer, Hatice
dc.contributor.authorOzhan, Mustafa Hikmet
dc.date.accessioned2019-10-27T21:53:45Z
dc.date.available2019-10-27T21:53:45Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: ERCC1 is considered as a promising molecular marker that may predict platinum based chemotherapy response in non small cell lung cancer patients. We therefore investigated whether its expression is indeed associated with clinical outcomes in advanced stage NSCLC patients. Materials and Methods: Pretreatment tumor biopsy samples of 83 stage 3B and 4 non-small cell lung cancer patients treated with platinum based chemotherapy were retrospectively analyzed for immunohistochemical ERCC1 expression. None of the patients received curative surgery or radiotherapy. Results: By calculating H- scores regarding the extent and intensity of immunohistochemical staining of tumor biopsy samples, ERCC1 expression was found to be positive in 50 patients (60.2%). ERCC1 positive and negative groups had no statistically significant differences regarding treatment response, progression free survival and overall survival (respectively p=0.161; p=0.412; p=0.823). Conclusions: In our study we found no association between ERCC1 expression and survival or treatment response. The study has some limitations, such as small sample size and retrospective analysis method. There is need of more knowledge for use of ERCC1 guided chemotherapy regimens in advanced stage NSCLC.en_US
dc.identifier.doi10.7314/APJCP.2013.14.8.4679en_US
dc.identifier.endpage4683en_US
dc.identifier.issn1513-7368
dc.identifier.issue8en_US
dc.identifier.pmid24083725en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage4679en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2013.14.8.4679
dc.identifier.urihttps://hdl.handle.net/11454/47957
dc.identifier.volume14en_US
dc.identifier.wosWOS:000328271800037en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectlung cancer chemotherapyen_US
dc.subjectERCC1en_US
dc.subjectmolecular markersen_US
dc.titleERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu